CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance for the Manoharan patent (application number 11/200,703), which covers several chemical classes of anti-miRs, antisense oligonucleotide inhibitors of microRNAs. This new patent in combination with Regulus’ existing intellectual property estate broadly covers approaches to developing microRNA-based therapeutics.
